The paradigm of mutant p53-expressing cancer stem cells and drug resistance

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1196-1208

  Shetzer, Yoav ^a   Solomon, Hilla ^a   Koifman, Gabriela ^a   Molchadsky, Alina ^a   Horesh, Stav ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; MUTANT PROTEIN; PROTEIN P53;

CANCER RECURRENCE; CANCER STEM CELL; CELL CYCLE REGULATION; CELL DEATH; CELL FUNCTION; CELL MOTILITY; CELL PLASTICITY; CELL SURVIVAL; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR INVASION; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MUTATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905372754     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu073     Document Type: Review

References (236)

1. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
2. Weinberg, R. (2013) The Biology of Cancer. Garland Science, New York. NY.
3. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
4. Levine, A.J. et al. (2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer, 9, 749-758.
5. Vousden, K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
6. Donehower, L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
7. Jacks, T. et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4, 1-7.
8. Purdie, C.A. et al. (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene, 9, 603-609.
9. Danilova, N. et al. (2008) p53 family in development. Mech. Dev., 125, 919-931.
10. Molchadsky, A. et al. (2010) p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis, 31, 1501-1508.
11. Rivlin, N. et al. (2014) p53 orchestrates between normal differentiation and cancer. Semin Cancer Biol.
12. Armstrong, J.F. et al. (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol., 5, 931-936.
13. Sah, V.P. et al. (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet., 10, 175-180.
14. Rinon, A. et al. (2011) p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development, 138, 1827-1838.
15. Rotter, V. et al. (1993) Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc. Natl Acad. Sci. USA, 90, 9075-9079.
16. Beumer, T.L. et al. (1998) The role of the tumor suppressor p53 in spermatogenesis. Cell Death Differ., 5, 669-677.
17. Bornstein, C. et al. (2011) SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol. Cell. Biol., 31, 1679-1689.
18. Hu, W. et al. (2007) p53 regulates maternal reproduction through LIF. Nature, 450, 721-724.
19. Levine, A.J. et al. (2011) The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol., 12, 259-265.
20. Molchadsky, A. et al. (2013) p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ., 20, 774-783.
21. Choi, J. et al. (1999) p53 in embryonic development: maintaining a fine balance. Cell. Mol. Life Sci., 55, 38-47.
22. El-Deiry, W.S. (1998) Regulation of p53 downstream genes. Semin. Cancer Biol., 8, 345-357.
23. Schmid, P. et al. (1991) Expression of p53 during mouse embryogenesis. Development, 113, 857-865.
24. Almog, N. et al. (1997) Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta, 1333, F1-F27.
25. Zambetti, G.P. et al. (2006) Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development. J. Cell Biol., 172, 795-797.
26. Shaulsky, G. et al. (1991) Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res., 51, 5232-5237.
27. Aloni-Grinstein, R. et al. (1993) Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene, 8, 3297-3305.
28. Montano, X. (1997) P53 associates with trk tyrosine kinase. Oncogene, 15, 245-256.
29. Zhang, J. et al. (2006) p53 is required for nerve growth factor-mediated differentiation of PC12 cells via regulation of TrkA levels. Cell Death Differ., 13, 2118-2128.
30. Hughes, A.L. et al. (2000) Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. Simultaneous differentiation and proliferation subsequent to p53 functional inactivation. J. Biol. Chem., 275, 37829-37837.
31. Brynczka, C. et al. (2007) NGF-mediated transcriptional targets of p53 in PC12 neuronal differentiation. BMC Genomics, 8, 139.
32. Tamir, Y. et al. (1998) p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene. Oncogene, 17, 347-356.
33. Porrello, A. et al. (2000) p53 regulates myogenesis by triggering the differentiation activity of pRb. J. Cell Biol., 151, 1295-1304.
34. Cam, H. et al. (2006) p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell, 10, 281-293.
35. Wang, X. et al. (2006) p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol., 172, 115-125.
36. Lengner, C.J. et al. (2006) Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol., 172, 909-921.
37. Molchadsky, A. et al. (2008) p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One, 3, e3707.
38. Radinsky, R. et al. (1994) Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene, 9, 1877-1883.
39. Armesilla-Diaz, A. et al. (2009) p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp. Cell Res., 315, 3598-3610.
40. Hallenborg, P. et al. (2009) The tumor suppressors pRB and p53 as regulators of adipocyte differentiation and function. Expert Opin. Ther. Targets, 13, 235-246.
41. Ng, H.H. et al. (2011) The transcriptional and signalling networks of pluripotency. Nat. Cell Biol., 13, 490-496.
42. Simons, B.D. et al. (2011) Strategies for homeostatic stem cell self-renewal in adult tissues. Cell, 145, 851-862.
43. Moore, K.A. et al. (2006) Stem cells and their niches. Science, 311, 1880-1885.
44. Lin, T. et al. (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol., 7, 165-171.
45. Solozobova, V. et al. (2010) Regulation of p53 in embryonic stem cells. Exp. Cell Res., 316, 2434-2446.
46. Aloni-Grinstein, R. et al. (2014) p53: the barrier to cancer stem cell formation. FEBS Lett.
47. Cicalese, A. et al. (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell, 138, 1083-1095.
48. Flesken-Nikitin, A. et al. (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature, 495, 241-245.
49. Rubio, R. et al. (2010) Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res., 70, 4185-4194.
50. Sarig, R. et al. (2010) Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med., 207, 2127-2140.
51. Takahashi, K. et al. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676.
52. Chambers, S.M. et al. (2011) Cell fate plug and play: direct reprogramming and induced pluripotency. Cell, 145, 827-830.
53. Graf, T. et al. (2009) Forcing cells to change lineages. Nature, 462, 587-594.
54. Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507.
55. Calvanese, V. et al. (2008) Cancer genes hypermethylated in human embryonic stem cells. PLoS One, 3, e3294.
56. Semi, K. et al. (2013) Cellular reprogramming and cancer development. Int. J. Cancer, 132, 1240-1248.
57. Zhao, Y. et al. (2008) Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell, 3, 475-479.
58. Banito, A. et al. (2009) Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev., 23, 2134-2139.
59. Hong, H. et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 460, 1132-1135.
60. Kawamura, T. et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature, 460, 1140-1144.
61. Li, H. et al. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 460, 1136-1139.
62. Marión, R.M. et al. (2009) A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 460, 1149-1153.
63. Utikal, J. et al. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 460, 1145-1148.
64. Takenaka, C. et al. (2010) Effective generation of iPS cells from CD34(+) cord blood cells by inhibition of p53. Exp. Hematol, 38, 154-162.
65. Johnson, F.B. et al. (1999) Molecular biology of aging. Cell, 96, 291-302.
66. Mondal, A.M. et al. (2013) p53 isoforms regulate aging-and tumorassociated replicative senescence in T lymphocytes. J. Clin. Invest., 123, 5247-5257.
67. Rodier, F. et al. (2007) Two faces of p53: aging and tumor suppression. Nucleic Acids Res., 35, 7475-7484.
68. Lim, D.S. et al. (2000) Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol. Cell. Biol., 20, 3772-3780.
69. Chin, L. et al. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 97, 527-538.
70. Varela, I. et al. (2005) Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature, 437, 564-568.
71. Collado, M. et al. (2007) Cellular senescence in cancer and aging. Cell, 130, 223-233.
72. Poyurovsky, M.V. et al. (2010) P53 and aging: a fresh look at an old paradigm. Aging (Albany NY), 2, 380-382.
73. Maier, B. et al. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev., 18, 306-319.
74. López-Otín, C. et al. (2013) The hallmarks of aging. Cell, 153, 1194-1217.
75. Shetzer, Y. et al. (2014, in press) The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death and Differentiation.
76. Petitjean, A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat., 28, 622-629.
77. Levine, A.J. et al. (1991) The p53 tumour suppressor gene. Nature, 351, 453-456.
78. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
79. Wolf, D. et al. (1984) Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell, 38, 119-126.
80. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
81. Olive, K.P. et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell, 119, 847-860.
82. Lang, G.A. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell, 119, 861-872.
83. Gonzalez, K.D. et al. (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J. Clin. Oncol., 27, 1250-1256.
84. Malkin, D. et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238.
85. Malkin, D. (2011) Li-Fraumeni syndrome. Genes Cancer 2, 475-484.
86. Freed-Pastor, W.A. et al. (2012) Mutant p53: one name, many proteins. Genes Dev., 26, 1268-1286.
87. Bisio, A. et al. (2014) TP53 mutants in the tower of babel of cancer progression. Hum. Mutat.
88. Buganim, Y. et al. (2010) p53 regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res., 70, 2274-2284.
89. Solomon, H. et al. (2012) Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J. Cell Sci., 125, 3144-3152.
90. Hanel, W. et al. (2013) Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ., 20, 898-909.
91. Lee, M.K. et al. (2012) Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell, 22, 751-764.
92. Rotter, V. (1983) p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl Acad. Sci. USA, 80, 2613-2617.
93. Terzian, T. et al. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev., 22, 1337-1344.
94. Di Agostino, S. et al. (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell, 10, 191-202.
95. Brosh, R. et al. (2010) Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol. Biosyst., 6, 17-29.
96. Wang, W. et al. (2013) Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis., 4, e574.
97. Song, H. et al. (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol., 9, 573-580.
98. Lu, X. et al. (2013) The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene, 32, 2900-2906.
99. Caulin, C. et al. (2007) An inducible mouse model for skin cancer reveals distinct roles for gain-and loss-of-function p53 mutations. J. Clin. Invest., 117, 1893-1901.
100. Hingorani, S.R. et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7, 469-483.
101. Murphy, K.L. et al. (2000) Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene, 19, 1045-1051.
102. Stephens, P.J. et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144, 27-40.
103. Kogan-Sakin, I. et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ., 18, 271-281.
104. Dong, P. et al. (2013) Mutant p53 gain-of-function induces epithelialmesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene, 32, 3286-3295.
105. Xia, M. et al. (2007) Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat. Struct. Mol. Biol., 14, 215-223.
106. Muller, P.A. et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell, 139, 1327-1341.
107. Yeudall, W.A. et al. (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis, 33, 442-451.
108. Fontemaggi, G. et al. (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol., 16, 1086-1093.
109. Famulski, W. et al. (2006) P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma, 53, 43-48.
110. Khromova, N.V. et al. (2009) p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett., 276, 143-151.
111. Tian, Y. et al. (2006) Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J. Gastroenterol., 12, 415-419.
112. Vander Heiden, M.G. et al. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-1033.
113. Zhang, C. et al. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun., 4, 2935.
114. Cooks, T. et al. (2014) Caught in the crossfire: p53 in inflammation. Carcinogenesis.
115. Weisz, L. et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res., 67, 2396-2401.
116. Cooks, T. et al. (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell, 23, 634-646.
117. McMurray, H.R. et al. (2008) Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature, 453, 1112-1116.
118. Scian, M.J. et al. (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol. Cell. Biol., 25, 10097-10110.
119. Madar, S. et al. (2013) Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One, 8, e61353.
120. Peled, A. et al. (1996) Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res., 56, 2148-2156.
121. Li, R. et al. (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene, 16, 3269-3277.
122. Blandino, G. et al. (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18, 477-485.
123. Buganim, Y. et al. (2006) Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res., 66, 10750-10759.
124. Stambolsky, P. et al. (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell, 17, 273-285.
125. Xie, T.X. et al. (2013) Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope, 123, 1416-1423.
126. Frisch, S.M. et al. (2001) Anoikis mechanisms. Curr. Opin. Cell Biol., 13, 555-562.
127. Matas, D. et al. (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J., 20, 4163-4172.
128. Chin, K.V. et al. (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459-462.
129. Bossi, G. et al. (2008) Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle, 7, 1870-1879.
130. Weisz, L. et al. (2004) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res., 64, 8318-8327.
131. Zalcenstein, A. et al. (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene, 22, 5667-5676.
132. Chee, J.L. et al. (2013) Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle, 12, 278-288.
133. Oren, M. et al. (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol., 2, a001107.
134. Irwin, M.S. et al. (2003) Chemosensitivity linked to p73 function. Cancer Cell, 3, 403-410.
135. Donzelli, S. et al. (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ., 19, 1038-1048.
136. Masciarelli, S. et al. (2014) Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene, 33, 1601-1608.
137. Dick, J.E. (2008) Stem cell concepts renew cancer research. Blood, 112, 4793-4807.
138. Vermeulen, L. et al. (2008) Cancer stem cells-old concepts, new insights. Cell Death Differ., 15, 947-958.
139. Lapidot, T. et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-648.
140. Bonnet, D. et al. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 3, 730-737.
141. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA, 100, 3983-3988.
142. Singh, S.K. et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res., 63, 5821-5828.
143. Li, C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res., 67, 1030-1037.
144. Ricci-Vitiani, L. et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature, 445, 111-115.
145. O'Brien, C.A. et al. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-110.
146. Zhang, S. et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res., 68, 4311-4320.
147. Curley, M.D. et al. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 27, 2875-2883.
148. Alvero, A.B. et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 8, 158-166.
149. Sugihara, E. et al. (2013) Complexity of cancer stem cells. Int. J. Cancer, 132, 1249-1259.
150. Yang, L. et al. (2013) Ovarian cancer stem cells enrichment. Methods Mol. Biol., 1049, 337-345.
151. Hirschmann-Jax, C. et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA, 101, 14228-14233.
152. Schatton, T. et al. (2008) Identification of cells initiating human melanomas. Nature, 451, 345-349.
153. Quintana, E. et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell, 18, 510-523.
154. Valent, P. et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer, 12, 767-775.
155. Mandal, P.K. et al. (2011) DNA damage response in adult stem cells: pathways and consequences. Nat. Rev. Mol. Cell Biol., 12, 198-202.
156. Tata, P.R. et al. (2013) Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature, 503, 218-223.
157. Wagers, A.J. et al. (2004) Plasticity of adult stem cells. Cell, 116, 639-648.
158. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
159. Donghi, R. et al. (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91, 1753-1760.
160. Fagin, J.A. et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 91, 179-184.
161. Yamaguchi, T. et al. (1996) Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res., 16, 2009-2015.
162. Kemp, C.J. et al. (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell, 74, 813-822.
163. Mizuno, H. et al. (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc. Natl Acad. Sci. USA, 107, 22745-22750.
164. Krizhanovsky, V. et al. (2009) Stem cells: the promises and perils of p53. Nature, 460, 1085-1086.
165. Sridharan, R. et al. (2009) Role of the murine reprogramming factors in the induction of pluripotency. Cell, 136, 364-377.
166. Wang, Y. et al. (2009) Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell, 15, 514-526.
167. Liu, C. et al. (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell, 146, 209-221.
168. Rubio, R. et al. (2013) The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene, 32, 4970-4980.
169. Rodriguez, R. et al. (2012) Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res., 22, 62-77.
170. Rodriguez, R. et al. (2009) Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia, 11, 397-407.
171. Choi, J. et al. (2010) Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am. J. Pathol., 177, 2645-2658.
172. Mutsaers, A.J. et al. (2014) Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone, 62C, 56-63.
173. Hiraga, T. et al. (2013) Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res., 73, 4112-4122.
174. Hermann, P.C. et al. (2010) Cancer stem cells in solid tumors. Semin. Cancer Biol., 20, 77-84.
175. Liu, C. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 17, 211-215.
176. Godar, S. et al. (2008) Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell, 134, 62-73.
177. Adhikari, A.S. et al. (2010) CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res., 70, 4602-4612.
178. Kang, M.K. et al. (2008) Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci., 9, 15.
179. Siemens, H. et al. (2013) Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget, 4, 1399-1415.
180. Qin, H. et al. (2007) Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J. Biol. Chem., 282, 5842-5852.
181. Wang, M.L. et al. (2013) Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther., 6, 1207-1220.
182. Jeter, C.R. et al. (2011) NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene, 30, 3833-3845.
183. Chiou, S.H. et al. (2010) Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res., 70, 10433-10444.
184. Sato, A. et al. (2013) Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells. Stem Cell Res., 11, 601-610.
185. Zbinden, M. et al. (2010) NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J., 29, 2659-2674.
186. Siemens, H. et al. (2011) miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle, 10, 4256-4271.
187. Korpal, M. et al. (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem., 283, 14910-14914.
188. Chang, C.J. et al. (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol., 13, 317-323.
189. Brosh, R. et al. (2013) p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ., 20, 312-320.
190. Li, L. et al. (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res., 66, 4553-4557.
191. Kerbel, R.S. et al. (1994) Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J. Cell. Biochem., 56, 37-47.
192. Thomas, H. et al. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control, 10, 159-165.
193. Fletcher, J.I. et al. (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer, 10, 147-156.
194. Holohan, C. et al. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer, 13, 714-726.
195. Dean, M. (2009) ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia, 14, 3-9.
196. Sophos, N.A. et al. (2003) Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem. Biol. Interact., 143-144, 5-22.
197. Magni, M. et al. (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood, 87, 1097-1103.
198. Moreb, J. et al. (1996) Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther., 3, 24-30.
199. Tanei, T. et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res., 15, 4234-4241.
200. Moreb, J.S. et al. (2000) Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J. Pharmacol. Exp. Ther., 293, 390-396.
201. + human breast cancer cells. Breast Cancer Res. Treat., 133, 75-87.
202. Ma, I. et al. (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev., 7, 292-306.
203. Deng, S. et al. (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, e10277.
204. Ishikawa, T. et al. (1993) Glutathione-associated cisdiamminedichloroplatinum( II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem., 268, 20116-20125.
205. Estrela, J.M. et al. (2006) Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci., 43, 143-181.
206. Ishikawa, T. (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci., 17, 463-468.
207. Perry, R.R. et al. (1993) Glutathione levels and variability in breast tumors and normal tissue. Cancer, 72, 783-787.
208. Tatebe, S. et al. (2002) Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int. J. Cancer, 97, 21-27.
209. Trachootham, D. et al. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 8, 579-591.
210. Ito, K. et al. (2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature, 431, 997-1002.
211. Diehn, M. et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458, 780-783.
212. Boyer, J. et al. (2004) Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res., 10, 2158-2167.
213. Hector, S. et al. (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol., 48, 398-406.
214. Metzger, R. et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol., 16, 309-316.
215. Dabholkar, M. et al. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 94, 703-708.
216. Lord, R.V. et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 8, 2286-2291.
217. Sarkaria, J.N. et al. (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res., 14, 2900-2908.
218. Fink, D. et al. (1998) The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4, 1-6.
219. Fink, D. et al. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56, 4881-4886.
220. Hawn, M.T. et al. (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res., 55, 3721-3725.
221. D'Atri, S. et al. (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol., 54, 334-341.
222. Bao, S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
223. Gallmeier, E. et al. (2011) Inhibition of ataxia telangiectasia-and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumorinitiating cell fraction. Stem Cells, 29, 418-429.
224. Bartucci, M. et al. (2012) Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ., 19, 768-778.
225. Karimi-Busheri, F. et al. (2010) Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res., 12, R31.
226. Chuang, S.E. et al. (2002) Basal levels and patterns of anticancer druginduced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol., 63, 1709-1716.
227. Liu, G. et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 5, 67.
228. Di Franco, S. et al. (2011) Colon cancer stem cells: bench-to-bedside-new therapeutical approaches in clinical oncology for disease breakdown. Cancers (Basel), 3, 1957-1974.
229. Ma, S. et al. (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 27, 1749-1758.
230. Oren, M. et al. (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol., 2, a001107.
231. Lane, D. et al. (2010) p53 research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol., 2, a001107.
232. Cheok, C.F. et al. (2011) Translating p53 into the clinic. Nat. Rev. Clin. Oncol., 8, 25-37.
233. Kawamura, T. et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature, 460, 1140-1144.
234. Sengupta, S. et al. (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol., 6, 44-55.
235. Shen, Y.A. et al. (2013) Resveratrol impedes the stemness, epithelialmesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evid. Based Complement. Alternat. Med., 2013, 590393.
236. Wu, S. et al. (2013) Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Biochem. Biophys. Res. Commun., 434, 898-903.